Cargando…

Uptake and Utilization of the Management of Anticoagulation in the Periprocedural Period App: Longitudinal Analysis

BACKGROUND: Anticoagulants are major contributors to preventable adverse drug events, and their optimal management in the periprocedural period is particularly challenging. Traditional methods of disseminating clinical guidelines and tools cannot keep pace with the rapid expansion of available thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Spyropoulos, Alex C, Myrka, Anne, Triller, Darren M, Ragan, Stephen, York, Collin, King, Jaz-Michael, Lee, Ti-Kuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320435/
https://www.ncbi.nlm.nih.gov/pubmed/30578235
http://dx.doi.org/10.2196/11090
_version_ 1783385225984737280
author Spyropoulos, Alex C
Myrka, Anne
Triller, Darren M
Ragan, Stephen
York, Collin
King, Jaz-Michael
Lee, Ti-Kuang
author_facet Spyropoulos, Alex C
Myrka, Anne
Triller, Darren M
Ragan, Stephen
York, Collin
King, Jaz-Michael
Lee, Ti-Kuang
author_sort Spyropoulos, Alex C
collection PubMed
description BACKGROUND: Anticoagulants are major contributors to preventable adverse drug events, and their optimal management in the periprocedural period is particularly challenging. Traditional methods of disseminating clinical guidelines and tools cannot keep pace with the rapid expansion of available therapeutic agents, approved indications for use, and published medical evidence, so a mobile app, Management of Anticoagulation in the Periprocedural Period (MAPPP), was developed and disseminated to provide clinicians with guidance that reflects the most current medical evidence. OBJECTIVE: The objective of this study was to assess the global, national, and state-level acquisition of a mobile app since its initial release and characterize individual episodes of use based on drug selection, procedural bleeding risk, and patient thromboembolic risk. METHODS: Data were extracted from a mobile app usage tracker (Google Analytics) to characterize new users and completed episodes temporally (by calendar quarter) and geographically (globally, nationally, and in the targeted US state of New York) for the period between April 1, 2016 and September 30, 2017. RESULTS: The app was acquired by 2866 new users in the measurement period, and the users completed nearly 10,000 individual episodes of use. Acquisition and utilization spanned 51 countries globally, predominantly in the United States and particularly in New York State. Warfarin and rivaroxaban were the most frequently selected drugs, and completed episodes most frequently included the selection of high bleeding risk (4888/9963, 49.06%) and high thromboembolic risk categories (4500/9963, 45.17%). CONCLUSIONS: The MAPPP app is a successful means of disseminating current guidance on periprocedural anticoagulant use, as indicated by broad global uptake and upward trends in utilization. Limitations in access to provider and patient-specific data preclude objective evaluation of the clinical impact of the app. An ongoing study incorporating app logic into electronic health record systems at participant health systems will provide a more definitive evaluation of the clinical impact of the app logic.
format Online
Article
Text
id pubmed-6320435
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-63204352019-01-28 Uptake and Utilization of the Management of Anticoagulation in the Periprocedural Period App: Longitudinal Analysis Spyropoulos, Alex C Myrka, Anne Triller, Darren M Ragan, Stephen York, Collin King, Jaz-Michael Lee, Ti-Kuang JMIR Mhealth Uhealth Original Paper BACKGROUND: Anticoagulants are major contributors to preventable adverse drug events, and their optimal management in the periprocedural period is particularly challenging. Traditional methods of disseminating clinical guidelines and tools cannot keep pace with the rapid expansion of available therapeutic agents, approved indications for use, and published medical evidence, so a mobile app, Management of Anticoagulation in the Periprocedural Period (MAPPP), was developed and disseminated to provide clinicians with guidance that reflects the most current medical evidence. OBJECTIVE: The objective of this study was to assess the global, national, and state-level acquisition of a mobile app since its initial release and characterize individual episodes of use based on drug selection, procedural bleeding risk, and patient thromboembolic risk. METHODS: Data were extracted from a mobile app usage tracker (Google Analytics) to characterize new users and completed episodes temporally (by calendar quarter) and geographically (globally, nationally, and in the targeted US state of New York) for the period between April 1, 2016 and September 30, 2017. RESULTS: The app was acquired by 2866 new users in the measurement period, and the users completed nearly 10,000 individual episodes of use. Acquisition and utilization spanned 51 countries globally, predominantly in the United States and particularly in New York State. Warfarin and rivaroxaban were the most frequently selected drugs, and completed episodes most frequently included the selection of high bleeding risk (4888/9963, 49.06%) and high thromboembolic risk categories (4500/9963, 45.17%). CONCLUSIONS: The MAPPP app is a successful means of disseminating current guidance on periprocedural anticoagulant use, as indicated by broad global uptake and upward trends in utilization. Limitations in access to provider and patient-specific data preclude objective evaluation of the clinical impact of the app. An ongoing study incorporating app logic into electronic health record systems at participant health systems will provide a more definitive evaluation of the clinical impact of the app logic. JMIR Publications 2018-12-21 /pmc/articles/PMC6320435/ /pubmed/30578235 http://dx.doi.org/10.2196/11090 Text en ©Alex C Spyropoulos, Anne Myrka, Darren M Triller, Stephen Ragan, Collin York, Jaz-Michael King, Ti-Kuang Lee. Originally published in JMIR Mhealth and Uhealth (http://mhealth.jmir.org), 21.12.2018. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR mhealth and uhealth, is properly cited. The complete bibliographic information, a link to the original publication on http://mhealth.jmir.org/, as well as this copyright and license information must be included.
spellingShingle Original Paper
Spyropoulos, Alex C
Myrka, Anne
Triller, Darren M
Ragan, Stephen
York, Collin
King, Jaz-Michael
Lee, Ti-Kuang
Uptake and Utilization of the Management of Anticoagulation in the Periprocedural Period App: Longitudinal Analysis
title Uptake and Utilization of the Management of Anticoagulation in the Periprocedural Period App: Longitudinal Analysis
title_full Uptake and Utilization of the Management of Anticoagulation in the Periprocedural Period App: Longitudinal Analysis
title_fullStr Uptake and Utilization of the Management of Anticoagulation in the Periprocedural Period App: Longitudinal Analysis
title_full_unstemmed Uptake and Utilization of the Management of Anticoagulation in the Periprocedural Period App: Longitudinal Analysis
title_short Uptake and Utilization of the Management of Anticoagulation in the Periprocedural Period App: Longitudinal Analysis
title_sort uptake and utilization of the management of anticoagulation in the periprocedural period app: longitudinal analysis
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320435/
https://www.ncbi.nlm.nih.gov/pubmed/30578235
http://dx.doi.org/10.2196/11090
work_keys_str_mv AT spyropoulosalexc uptakeandutilizationofthemanagementofanticoagulationintheperiproceduralperiodapplongitudinalanalysis
AT myrkaanne uptakeandutilizationofthemanagementofanticoagulationintheperiproceduralperiodapplongitudinalanalysis
AT trillerdarrenm uptakeandutilizationofthemanagementofanticoagulationintheperiproceduralperiodapplongitudinalanalysis
AT raganstephen uptakeandutilizationofthemanagementofanticoagulationintheperiproceduralperiodapplongitudinalanalysis
AT yorkcollin uptakeandutilizationofthemanagementofanticoagulationintheperiproceduralperiodapplongitudinalanalysis
AT kingjazmichael uptakeandutilizationofthemanagementofanticoagulationintheperiproceduralperiodapplongitudinalanalysis
AT leetikuang uptakeandutilizationofthemanagementofanticoagulationintheperiproceduralperiodapplongitudinalanalysis